Chinese firmâs COVID-19 drug claims draw scientistsâ skepticism By Syndicated Content
By Gabriel Stargardter
(Reuters) â Chinese biotech firm Kintor Pharmaceutical Limited [9939.HK] saw its stock price jump by more than 20% the day after it announced on April 25 that it had âcompleted the first patient enrollment and dosingâ in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the companyâs latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed companyâs stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.
Scientists skeptical over Chinese firm s Covid-19 drug claims, firm s stocks surge Reuters Chinese Covid drug
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrollment and dosing in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.
Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had "completed the first patient enrollment and dosing" in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
By Gabriel Stargardter
May 14 (Reuters) - Chinese biotech firm Kintor Pharmaceutical Limited saw its stock price jump by more than 20% the day after it announced on April 25 that it had completed the first patient enrollment and dosing in a late-stage U.S. clinical trial of its experimental COVID-19 treatment.
It was the company s latest announcement about the progress of the drug, Proxalutamide. The Hong Kong-listed company s stock price has nearly quadrupled since March 1 as some analysts wrote about the big sales potential for a COVID-19 treatment. Kintor has seen its market capitalization soar to HK$23.4 billion ($3 billion) from HK$6.6 billion ($850 million) on March 1.
11 Min Read
RIO DE JANEIRO, May 14 (Reuters) - Brazilian President Jair Bolsonaro, addressing the nation last month in a social media video, touted the latest in a string of unconventional drugs he says can ease the country’s COVID-19 crisis.
Bolsonaro - a vaccine skeptic and promoter of discredited treatments such as hydroxychloroquine - said this new drug, Proxalutamide, would “soon be available to all Brazil.” He invited a little-known Health Ministry official, Helio Angotti, to expand on its promise.
Angotti, an eye doctor with no epidemiological experience, cited a domestic Proxalutamide study showing a 92% decrease in mortality risk among hospitalized COVID-19 patients. It was a dramatic claim amid a global struggle to find effective treatments. He said he aimed to “get it to the Brazilian population as soon as possible.”